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Abstract
Purpose: Reperfusion therapies are medical treatments that restore blood flow either by surgical removal of a blood clot or
with medications that dissolve clots. The introduction of reperfusion therapies has the potential to change the presentation
of aphasia following acute ischaemic stroke (AIS). This scoping study will explore the relationship between aphasia and
reperfusion therapies from a speech-language pathology perspective.
Method: A systematic literature search was performed on studies published up until October 2016. Relevant studies that
reported on aphasia and reperfusion therapy were assessed for quality and the relationship between the two.
Results: Overall, 27 studies were identified, these studies were heterogeneous in nature. Despite speech-language
pathologists filling a central role in management of aphasia, only seven of these studies mentioned involvement of speech-
language pathologists, with minimal information about the precise nature of the involvement of speech-language pathology
services.
Conclusion: Based on this scoping review, reperfusion therapy appears to be impacting on the presentation of aphasia. A
prospective study into reperfusion therapy and aphasia is required to inform speech-language pathologists on this patient
population.
Keywords: aphasia; thrombolysis; thrombectomy; ischaemic stroke
Introduction
Acute ischaemic stroke (AIS), a blood clot in the
brain, makes up more than 80% of the strokes in
Western countries (Zhang et al., 2014). Stroke is
associated with significant long-term disability and is
the most common cause of aphasia (Miller,
Hartwell, & Lewandowski, 2012). Aphasia is present
in 21–38% of acute stroke patients (Pedersen,
Jørgensen, Nakayama, Raaschou, & Olsen, 1995)
with studies indicating that language is still impaired
in over half of the patients 12–18 months after stroke
(Denier et al., 2016). Changes in medical treatments
provided in the hyper-acute setting (within the first
24 hours of arrival to hospital) can potentially
change the presentation of post-stroke symptoms,
such as aphasia. When these hyper-acute medical
treatments are utilised, early restoration of blood
flow can be achieved, resulting in reductions in the
size, pattern, and nature of infarcts following AIS
(Martins et al., 2016).
A National Institute of Neurological Disorders
and Stroke (NINDS, 1995) trial initiated a shift
towards hyper-acute medical treatments for AIS that
restore blood flow to the brain. Hyper-acute treat-
ments known as reperfusion therapies, included
intravenous (IV), intra-arterial (IA) or combined
IV–IA thrombolysis, and mechanical thrombectomy
(Alonso de Lecinana et al., 2014; Layton, White,
Cloft, Kallmes, & Manno, 2006; Nguyen et al.,
2011). The conclusion drawn from the NINDS
(1995) trial was that despite an increased incidence
of symptomatic intracerebral haemorrhage, treat-
ment with IV thrombolysis within three hours of
onset improved clinical outcomes at three months
following AIS.
Reperfusion therapies target areas of hypo-perfu-
sion, which are areas of reduced blood flow
(Robinson, Zaheer, & Mistri, 2011). Hypo-perfusion
causes hypoxia (reduced oxygenation) and temporary
loss of function to an area of the brain. This area of
temporary loss of function is referred to as the
penumbra. The penumbra surrounds an area of cell
death called the ‘‘core’’. If blood flow is restored
quickly to the penumbra, permanent damage can be
minimised, and clinical outcomes may be improved,
Correspondence: Victoria Jones, The University of Queensland, School of Health and Rehabilitation Sciences, 84A Therapies building, St Lucia QLD 4072,
Australia. Email: Victoria.Jones@uqconnect.edu.au
ISSN 1754-9507 print/ISSN 1754-9515 online  2018 The Speech Pathology Association of Australia Limited
Published by Informa UK Limited, trading as Taylor & Francis Group
DOI: 10.1080/17549507.2018.1448894
leading to the recovery of function (Zhang et al.,
2014). It is therefore important that reperfusion
therapies are provided as soon as possible. Globally,
the percentage of patients receiving the most
common type of reperfusion, IV recombinant
tissue-type plasminogen activator (rtPA), varies
from 1–12% across countries; 7% in Australia (The
National Stroke Foundation, 2015), 11–12% in the
UK (Royal College of Physicians, 2015), 9% in
Qatar, 5.1% in the USA, 8.6% in Sweden
(Hoffmeister et al., 2016). Quain et al. (2008)
suggested that the percentage of patients treated by
reperfusion therapies could increase to up to 20%, a
number that individual specialised stroke units with
thrombolysis protocols have successfully achieved.
IV alteplase, a form of rtPA, has become the
emerging standard of care for patients with AIS who
present to the emergency department. IV alteplase
must be administered within 4.5 hours of onset of
symptoms (Denier et al., 2016). Current eligibility
criteria for IV alteplase include: arrival with
4.5 hours of stroke onset, National Institutes of
Health Stroke Scale (NIHSS) of 44, CT with no
signs of haemorrhage, patients’ age is418 years old.
Exclusion criteria for IV alteplase include: uncer-
tainty about time of onset, hypertension, septic
embolus, and recent use of blood thinning medica-
tion such as heparin. If used within the recom-
mended guidelines, IV alteplase is associated with a
significant net reduction in death and disability in
those treated with IV alteplase compared with those
treated with placebo (52.4% versus 45.2%, respect-
ively; OR, 1.34; 95% CI, 1.02–1.76; p¼ .04) despite
a small but significant increase in the risk of
intracerebral haemorrhage (ICH) (2.4% versus
0.2%, p¼ .008) (Robinson et al., 2011).
Another form of reperfusion therapy involves
delivering alteplase via arteries rather than veins.
Crijnen et al. (2016) recently reported intra-arterial
treatment (IAT) with retrievable stents for patients
with AIS improves functional outcome at 90 days.
The main advantage of IAT reperfusion therapy, over
IValteplase, is that it allows direct delivery of a highly
concentrated thrombolytic drug to the clot (Nguyen
et al., 2011). Another benefit is IAT reduces the risk
of systemic side effects (i.e., allergic reaction, by
minimising the use of chemical thrombolytics, this
decreases the risk of ICH, and reduces the risk of
increased blood brain barrier permeability and
oedema) and can be delivered up to six hours post-
stroke. IAT is not as prevalent, however, as it is a
costly therapy requiring expensive devices, highly
trained proceduralists, periprocedural support from
interventional teams including anaesthesiology and
close post procedure monitoring (Leppert,
Campbell, Simpson, & Burke, 2015).
For patients who are ineligible for IV rtPA or IAT,
due to possible interactions with medications or pre-
existing medical conditions, mechanical thrombec-
tomy is an alternative stroke therapy (Zhang et al.,
2014). Mechanical thrombectomy involves the inser-
tion of a catheter into effected blood vessel. Once at
the blood clot, a stent is used to remove the blood clot
instead of dissolving it. Clinical experience with
mechanical thrombectomy is limited, expensive and
requires specialised unit with extensive training.
Despite the introduction of reperfusion therapies, in
acute stroke management, many patients still require
inpatient rehabilitation and treatment from speech-
language pathologists for aphasia (Meyer et al.,
2012). Speech-language pathologists are needed to
rehabilitate patients post stroke, often to target
dysphagia, dysarthria, apraxia and/or aphasia.
Patients with aphasia can experience expressive
and/or receptive language impairments for several
months or years following stroke; often leading to
difficulty in investing in rehabilitation and under-
standing therapist’s instructions, depression, social
drawback, decreased professional activities, and
altogether a lower quality of life (Power et al.,
2015). Given the prevalence of aphasia following
stroke and the increasing use of reperfusion thera-
pies in acute stroke management, there is a high
likelihood that speech-language pathologists will
increasingly manage patients with aphasia who
have received reperfusion therapies as part of their
stroke management in acute and rehabilitation
settings. The aim of this scoping review is to
investigate the relationship between the introduction
of reperfusion therapies and aphasia.
Method
A scoping review method was adopted to explore the
depth of evidence regarding the relationship between
reperfusion therapies and aphasia. Scoping reviews
are a relatively recent addition to healthcare litera-
ture and represent an increasingly popular approach
to reviewing literature (Davis, Drey, & Gould,
2009). Scoping reviews are particularly relevant to
disciplines with emerging evidence, such as rehabili-
tation science, in which the paucity of randomised
controlled trials makes it difficult for researchers to
undertake systematic reviews (Levac, Colquhoun, &
O’Brien, 2010). Unlike systematic reviews, which
use narrow questions and a predetermined level of
acceptable quality of studies; scoping reviews use a
broad question and include all relevant studies.
Scoping reviews differ from narrative or literature
reviews in that the scoping process requires analysis
of common data presented in the source literature
and reinterpretation of hypotheses using the com-
bined data (Levac et al., 2010).
A scoping review provides an appropriate method
to systematically evaluate a heterogeneous area of
research to identify gaps in the existing literature by
allowing variation in methods between studies
selected to be included (Armstrong, Hall, Doyle, &
Waters, et al., 2011). As per the scoping review
process, developed by Arksey and O’Malley (2005)
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and Levac et al. (2010), all the literature within a
defined set is summarised, regardless of its quality,
to examine the range of studies that exist.
Literature search
A systematic literature search was performed on
studies published up until October 2016 on Web of
science, Medline, CINAHL, Cochrane database of
systematic reviews and EMBASE. Search terms
included for reperfusion therapy (thrombolysis;
tissue plasminogen activator; alteplase; arterial
thrombolysis; fibrinolytic agent; urokinase; thromb-
ectomy); combined it with a communication term
(aphasia; cognitive communication; language impair-
ment); and medical diagnosis (stroke; middle cerebral
artery occlusion; brain infarction; brain ischemia).
Inclusion and exclusion criteria
The studies included in this scoping review met the
following criteria: (1) individuals who have experi-
enced an ischaemic stroke; (2) studies that identify
the use of thrombolysis and/or thrombectomy and the
presence of aphasia; (3) studies published in English.
The studies excluded from this scoping review
met the following criteria: (1) individuals under the
age of 18; (2) studies that primarily discussed
thrombolysis and/or thrombectomy for cardiac
clots; (3) studies on mimic strokes; (4) studies on
brain tumours and other neurological issues; (5)
studies that briefly mention aphasia in introduction
but not in results (‘‘minimal aphasia’’); (6) studies
that briefly mention thrombolysis without providing
outcomes (‘‘minimal thrombolysis’’).
Data analysis
The studies were graded using a critical review form
developed by McMaster University Occupational
Therapy Evidence-Based Practice Research Group
(Law et al., 1998). The critical review form was used
to provide each study with a score out of 14. Each
question was assigned a value of one for ‘‘yes’’ and
zero for ‘‘no’’. Each study was assessed according to
its: 1) Study purpose and inclusion of background
literature; 2) sample, including description of the
patient sample and drop outs; 3) outcome measures;
4) description of the intervention used; 5) reporting of
results; and 6) conclusion. The designs of the studies
were categorised but not included in the scoring. Two
assessors reviewed each study and any differences in
scores were discussed until a consensus was reached.
Result
The literature search initially revealed 302 studies,
which after screening for title and abstract, was
reduced to 43 studies for full text analysis. An
additional thirty-eight studies were identified in the
reference sections. A flowchart of the literature
search and selection process can be seen in
Figure 1. Twenty-seven studies met the criteria for
inclusion and were assessed. Eleven of the studies
reviewed were retrospective studies that utilised data
collected from databases. These databases were
established with the intent to monitor and improve
management of acute stroke care. The 11 studies
used data collected from three large prospective
studies or eight regional databases that were not
designed for in-depth investigation of aphasia. These
databases were established by medical facilities to
collect baseline demographic and stroke-related
data, such as the Erlangen Stroke and
Thrombolysis Database or the Careggi Hospital
Acute Stroke Registry (Kohrmann et al., 2009; Nesi,
Lucente, Nencini, Fancellu, & Inzitari, 2014).
Study characteristics
Studies included in the current review were hetero-
geneous in nature. For example, as presented in
Table I, the number of participants ranged from 1 to
1007; the ages of participants, ranged from 28–82;
percentage of females included in studies (excluding
single case studies) ranged from 25–52%; and length
of follow-up varied from 24 hours to one year
following reperfusion therapy.
Outcome measures
Aphasia was most commonly assessed using the
NIHSS, the NIHSS is a quantitative measure of
stroke-related neurological deficits, it includes assess-
ment of: level of consciousness, speech and language
function, neglect, visual fields, eye movements, facial
symmetry, motor strength, sensation and coordin-
ation (Kasner et al., 2003). Due to the broad scope of
areas assessed by the NIHSS, a diagnosis of aphasia is
based on picture naming, picture description (the
Cookie theft) and sentence reading if based on item 9
(best language) with a maximum score of three. Items
1b (LOC questions) add questions about the month
and age, and item 1c (LOC commands) add one-
stage commands. As noted in Table I, additional
language assessments used included the Language
Screening Test (LAST) (Denier et al., 2016); the
Western Aphasia Battery (WAB) (Finch et al., 2014);
the French version of the Boston Diagnostic Aphasia
Examination (BDAE) (Jacquin et al., 2014); the
Lisbon Aphasia Assessment Battery (BAAL)
(Martins et al., 2016); and the Basel–Minnesota
test (Engelter et al., 2006). The study by de Oliveira
and Damasceno (2011) diagnosed aphasia with a
collection of informal language tasks described as
spontaneous narrative, fluency, yes/no and three
stage command, naming six objects and ideomotor
praxis. In 11 of the studies, follow-up was assessed
with the modified Rankin Scale (mRS) (Table I). The
mRS is a seven-point scale that progresses from 0 (no
symptoms) to 6 (death) with varying levels of
disability (Lubeck et al., 2016).
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Medical imaging was an additional measure of
impairment, with one or a combination of computed
tomography (CT), magnetic resonance (MR) or of
transcranial Doppler (TCD) performed at baseline,
prior to reperfusion therapy in 25 of the studies.
Twenty-three of the studies screened functional
impairment with the NIHSS as per the national
stroke guidelines. A repeat imaging scan was also
completed at follow-up in 16 of the 25 studies,
however, the same method of imaging was not
always used making pre-post comparisons difficult.
Three studies used imaging alone as their method of
assessment (Table I).
Core concepts
The literature revealed two core concepts between
the relationship between aphasia and thrombolysis
and/or thrombectomy (1) Studies that examined
isolated aphasia as a predictor for the need to treat
patients with reperfusion therapy regardless of the
NIHSS score (Kohrmann et al., 2009; Lundstrom,
Zini, Wahlgren, & Ahmed, 2015; Nesi et al., 2014)
and (2) Studies that established aphasia as a lasting
symptom of stroke following the use of endovascular
therapies. These two core concepts will now be
explored in this scoping review.
Core concept one: aphasia as a predictor
Thirteen of the 27 studies reviewed (Table I)
discussed the relationship between aphasia and the
need for reperfusion therapy (44 case studies, 8
cohort studies and 1 cross-sectional study). Nesi
et al. (2014) suggested that aphasia, as a presenting
symptom, strongly predicted negative outcomes in
ischaemic stroke patients. Global aphasia can predict
a poor prognosis in acute ischaemic stroke (de
Oliveira & Damasceno, 2011).
Engelter et al. (2006) and Kohrmann et al. (2009)
identified that patients presenting with aphasia as a
symptom were significantly more likely to receive
reperfusion therapy. Four of the studies (Cho,
Hermier, & Nighoghossian, 2010; Denier et al.,
2016; Lundstrom et al., 2015; Mazza et al., 2012)
concluded that patients with aphasia, in the absence
of physical symptoms, should still receive reperfusion
therapy even if the patient presents with a low
NIHSS. Cho et al. (2010) commented that the
natural course of aphasia leaves patients at risk of
severe deterioration, while Denier et al. (2016)
concluded that the diagnosis of aphasia alone on
early assessment independently predicted a worse
outcome. Mazza et al. (2012) indicated that the
presentation of aphasia alone resulted in a low
NIHSS score, and suggested that there should be a
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more personalised case by case approach to admin-
istering reperfusion therapy. Multiple authors agreed
that reperfusion therapy should be based on individ-
ual circumstances, rather than strict adherence to
guidelines (Cho, Hermier, & Nigjoghossian, 2010;
Denier et al., 2016; Pelletier, Bugeaud, Ibrahim,
Morency, & Kouz, 2010). Leishangthem and Satti
(2014) also highlighted the importance of using the
right type of reperfusion therapy for the patient, as in
their case study, the patient’s aphasia did not improve
after IV rtPA, however, the patient made a full
recovery following a subsequent mechanical
thrombectomy.
There has been some suggestion that patients with
aphasia due to a minor stroke may receive less benefit
from reperfusion therapies. Kremer et al. (2014) and
Maas et al. (2012) proposed arguments against using
isolated aphasia as an indication for reperfusion
therapy. Both study arguments were based on a
clinically suspected dissociation between a good early
outcome from aphasia in minor strokes relative to
recovery of other neurological deficits; as opposed to
a better recovery from other neurological deficits than
from aphasia in patients with severe strokes.
Core concept two: aphasia as an ongoing symptom post
reperfusion therapy
Fourteen of the 27 studies, summarised in Table I,
discussed aphasia as a persisting symptom following
reperfusion therapy. When comparing mobility out-
comes to aphasia outcomes, four of these studies
have reported that mobility outcomes greatly
improve, whereas aphasia appears to remain persist-
ent in isolation, following IV and mechanical
reperfusion therapy (Crijnen et al., 2016; Layton
et al., 2006; Santos et al., 2014; Tassi et al., 2013).
Two case studies, one reported by Chan, Cordato,
Kehdi, Schlaphoff, & McDougall (2008) the other by
Saarinen, Sillanpaa, & Kantola (2015) described
similar patients with a baselines that included dense
hemiplegia, global aphasia and a marked facial droop.
In both case studies, the patients received mechanical
reperfusion therapy. Each case study reported almost
complete resolution of symptoms, with aphasia as the
sole remaining symptom.
Reperfusion therapy does appear to improve the
severity of aphasia during the first week to 3 months
post-stroke when studies compare patients who have
been thrombolysed with non-thrombolysed patients.
For example, Crijnen et al. (2016) compared 126
patients who received IAT with 162 controls. When
language scores were measured at 24 hours and 1
week, it was noted that IAT resulted in better early
recovery of aphasia, however, the effect of IAT was
smaller than the effect on motor deficits at both
points in time. A case study by Finch et al. (2014)
found that of the four patients who received
reperfusion therapy, in the form of IV rtPA, three
of the four still required speech-language pathology
services three months’ post, for treatment of aphasia
(2 mild aphasia, 2 severe aphasia).
Larger studies designed to identify trends in
neurological recovery post reperfusion therapy also
noted that certain deficits often had only a partial
improvement, these included facial motor strength,
aphasia and dysarthria (Felberg et al., 2002). Kremer
et al. (2013) noted that early ischaemic changes were
not a predictor of improvement in aphasia in patients
receiving IV reperfusion therapy rtPA in the hyper-
acute phase. Furthermore, two-thirds of those diag-
nosed with aphasia remained unchanged, prompting
Kremer et al. (2013) to recommend a close follow-up
of language functions at the acute stage.
The role of speech-language pathology
Speech-language pathology involvement was noted
in seven of the 27 studies (Table II). Kremer et al.
(2013) reported that 31 of the 50 patients in their
study were seen by a speech-language pathologist to
confirm the diagnosis of aphasia. In the study by
Jacquin et al. (2014), for patients to be included in
the study aphasia had to be clinically diagnosed by a
speech-language pathologist. Jacquin et al. (2014)
noted that the severity of aphasia during the first
week and at 3 months following AIS stroke was
milder in the patients that received thrombolysis.
The authors also noted that patients treated with
thrombolysis initially presented with a greater fre-
quency of conduction and mild atypical aphasia. In
their large multicentre study Engelter et al. (2006)
also only included patients who had their aphasia
diagnosed by a speech-language pathologist.
None of the 27 studies described the speech-
language pathology intervention in detail, although
this was not unexpected considering the studies were
primarily written from a medical perspective. Only
three of the seven studies (Denier et al., 2015; Finch
et al., 2014; Jacquin et al., 2014) mentioned speech-
language pathology management beyond adminis-
tering assessments. Denier et al. (2015) reported
patients with aphasia received daily speech and
language therapy from baseline to discharge when
appropriate. Finch et al. (2014) reported all four
patients were assessed by a speech-language patholo-
gist, with three of the four patients requiring speech-
language pathology at discharge. A case study by
Layton et al. (2006) noted that their patient was
discharged to a rehabilitation centre for further
speech-language pathology intervention. At the time
of discharge, she had regained mobility of her right
side and improved her language deficit to a moderate
expressive aphasia. Jacquin et al. (2014) also noted
whether the patients were discharged to a rehabilita-
tion centre, for speech-language pathology treatment
alone or whether the patient received no follow-up.
Five of the 27 studies looked at improvements in
aphasia three months post stroke (Finch et al., 2014;
Kremer et al., 2014; Leishangthem & Satti, 2014;
8 V. Jones et al.
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Lundstrom et al., 2015; Nesi et al., 2014). The rest
of the studies look at aphasia until discharge from
the acute setting.
Study quality
All 27 studies reviewed were analysed with the
McMasters critical review form (Law et al., 1998).
The data extracted from this analysis is presented as
a harvest plot in Figure 2. None of the studies
received the maximum score of 14, the highest score
(11), was received by only four studies (Kohrmann
et al., 2009; Kremer et al., 2013; Lundstrom et al.,
2015; Martins et al., 2016). A strength of all studies
were the conclusions, the conclusions were deemed
appropriate in all but two studies, Mazza et al.
(2012) and Saarinen et al. (2015). The next strength
was the results section where all the studies reported
the clinical importance of their study. However, their
results were not always discussed in terms of
statistical significance, which was largely because
11 of the studies were single case studies.
Twelve of the studies recorded outcomes by
assessing aphasia with the NIHSS. However,
Martins et al. (2016) reported that the NIHSS
alone is insufficient for providing a diagnosis of
aphasia. The NIHSS is considered a valid and
commonly used stroke impairment scale that sums
the scores from individual elements of neurological
examination to provide an overall stroke impairment
score, and is considered reliable in the setting of
emergent stroke evaluation (Maas et al., 2012).
However, when it comes to diagnosing aphasia, the
NIHSS is a relatively crude instrument for language
assessment, as the measure does not explore lan-
guage comprehension or expression in detail.
Another strength of the reviewed studies was that
all 27 of the studies reviewed had a clearly stated
purpose, however, many were missing a thorough
review of background literature.
Discussion
Since the USA Food and Drug Administration
(FDA) approval in 1996, there has been a small,
yet gradual increase in the utilisation of rtPA for
treatment of AIS (Lubeck et al., 2016). Results from
the NINDS (1995) Study Group demonstrated that
rtPA improved functional outcome after ischaemic
stroke when given within three hours of symptom
onset. Research into reperfusion therapies has
focussed to date on safety and efficacy along with
functional improvement in general, we now need
more detailed examination about its impact on the
recovery of specific functions, such as communica-
tion. Consequently, this scoping review explored the
relationship between aphasia and the emerging use
of reperfusion therapy, with two core concepts
emerging within the literature. The first concept
was that aphasia could potentially predict the need
for reperfusion therapy. The second concept was
that aphasia was one of the last symptoms to resolve
post reperfusion therapy. There was a lack of long-
term follow-up with only two studies following-up
aphasia scores six months post stroke (Jacquin et al.,
2014; Maas et al., 2012). Since much of the research
into the relationship between reperfusion therapies
0
2
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10
12
14
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RE
Study purpose and literature Sample
STUDY (FIRST AUTOR)
Outcomes Results Intervenon Conclusions
Figure 2. The McMasters critical review form (Law et al., 1998) was used to analyze the 27 studies. The data extracted from this analysis is
presented here as a harvest plot. ‘‘Maximum Score’’ indicates maximum score per assessment criteria.
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and aphasia has been conducted from a medical
standpoint, the assessment used to diagnose aphasia
in most of these studies, such as the NIHSS or
composite assessments made up of NIHSS subtests,
was not ideal for diagnosing aphasia. These three
subtests provide a reliable yet insensitive measure of
aphasia.
Aphasia and reperfusion therapy is an important
area to research as aphasia not only causes functional
disability but impairs quality of life. Speech-lan-
guage pathology involvement within the emergency
setting may be indicated, as aphasia alone appears to
be an indicator of the need for reperfusion therapy,
there may be a role for a quick and comprehensive
aphasia assessment designed by speech-language
pathologists, to use along with the NIHSS. A
specific language screener like the LAST be com-
pleted prior to reperfusion therapy to compliment
global stroke scales (Denier et al., 2015). The
changing needs of this patient population in the
rehabilitation setting also requires further research.
Despite the success of reperfusion therapies, the
studies reviewed in this scoping review indicate that
this patient population may need to prioritise
assessment and treatment by a speech-language
pathologist, as aphasia appears to be a persisting
symptom. Twenty-five of the 27 studies included in
the review had ceased following up patients by three
months post-stroke. The longest time between
treatment with reperfusion therapy and follow up
assessment was six months, only two studies
included a six-month follow-up (Jacquin et al.,
2014; Maas et al., 2012). Given the persisting
nature of aphasia, there is a need for research into
longer term outcomes (e.g. 12 months).
The majority of the studies reviewed in this
scoping review were case studies or cohort studies,
making up 40% and 44% of the studies included,
respectively. The methodological quality of the
studies varied greatly with scores ranging from two
to eleven out of a possible fourteen on the critical
review form developed by Law et al. (1998). This
suggests room for longer more robust rigorous
studies into aphasia and reperfusion. There was a
distinct lack of cohesion between studies, with many
of these studies identifying themselves as the first to
look at the relationship between aphasia and thromb-
olysis without referring to the relevant earlier studies.
Research into reperfusion therapy and how it is
impacting on aphasia is progressing laterally, with
several sites investigating similar questions, because
more recent studies are not referring to older studies
available, research is not progressing in a united
manner. The goal of this scoping review is to bring the
current literature together and identify the next step.
Limitations of this study include restricting the
searches solely to papers published in English.
Another limitation is the literature search was run
twice and screened by one researcher.
Future research
As the use of reperfusion therapies becomes wide
spread, speech-language pathologists are going to
encounter this patient population more frequently.
This scoping review has uncovered a number of areas
for future research. One possible area of research is
within the emergency department, investigating the
current methods of diagnosing aphasia during the
hyper-acute phase. Another is within the rehabilita-
tion setting, looking at the natural progression of
aphasia post thrombolysis and development of spe-
cialised treatment plans. Medical imaging could be
conducted to see if there is an emerging pattern
between the scans and presentation of aphasia.
Twenty-five of the 27 studies included in the review
had ceased following up patients by three months
post-stroke. Given the persisting nature of aphasia,
there is a need for research into longer term outcomes
(e.g. 12 months).
Conclusion
In this scoping review, a total of 27 studies were
examined to ascertain the current state of published
literature on reperfusion therapies and aphasia.
Assessment of the literature revealed two common
themes: that a patient with AIS presenting with
aphasia should be considered for reperfusion therapy
and that aphasia is one of the last symptoms to
remain post reperfusion therapy. This scoping
review also identified a gap in the current literature,
with only seven of the studies mentioning speech-
language pathology, despite the key role speech-
language pathologists play in assessing, diagnosing
and treating aphasia. More research is required from
a speech-language pathologist’s perspective. Speech-
language pathologists treating adults following AIS
will benefit from additional information focussed on
how the various forms of reperfusion therapies are
impacting on the natural progression of aphasia, to
ensure speech-language pathologists are effectively
assessing and treating this patient population.
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